Moleculin Biotech Regains Nasdaq Compliance
I'm PortAI, I can summarize articles.
Moleculin Biotech received a deficiency letter from Nasdaq on June 27, 2025, for its stock price falling below $1.00. By December 15, 2025, the company regained compliance as its stock price met the required threshold for 10 consecutive business days. The latest analyst rating on MBRX stock is a Buy with a $31.00 price target. However, TipRanks' AI Analyst rates MBRX as Neutral due to high financial risk, no revenue, and growing losses.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments